Trevi Therapeutics (TRVI)
(Real Time Quote from BATS)
$3.52 USD
+0.19 (5.71%)
Updated Sep 18, 2024 01:50 PM ET
3-Hold of 5 3
D Value F Growth C Momentum F VGM
Cash flow Statements
Fiscal Year End for Trevi Therapeutics, Inc falls in the month of December.
All data in Millions except Per Share data.
Cash Flow From Operations, Investments & Financial Activities
12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 | |
---|---|---|---|---|---|
Cash Flow From Operations, Investments & Financial Activities |
|||||
Net Income (Loss) | -29.07 | -29.15 | -33.94 | -32.76 | -26.05 |
Depreciation/Amortization & Depletion | 0.30 | 0.56 | 0.65 | 0.27 | 0.04 |
Net Change from Assets/Liabilities | -3.85 | -1.23 | 1.51 | 1.06 | 1.58 |
Net Cash from Discontinued Operations | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Other Operating Activities | 0.90 | 1.65 | 2.84 | 2.43 | 1.34 |
Net Cash From Operating Activities | -31.71 | -28.18 | -28.95 | -29.00 | -23.09 |
Property & Equipment | -0.14 | -0.16 | 0.00 | -0.03 | -0.01 |
Acquisition/ Disposition of Subsidiaries | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Investments | 59.57 | -107.21 | 0.00 | 0.00 | 0.00 |
Other Investing Activities | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Net Cash from Investing Activities | 59.43 | -107.37 | 0.00 | -0.03 | -0.01 |
Uses of Funds
12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 | |
---|---|---|---|---|---|
Issuance (Repurchase) of Capital Stock | 0.14 | 117.39 | 13.72 | 0.05 | 75.10 |
Issuance (Repayment) of Debt | -9.50 | -5.83 | 0.00 | 14.00 | 0.00 |
Increase (Decrease) Short-Term Debt | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Payment of Dividends & Other Distributions | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Other Financing Activities | 1.45 | -0.25 | 7.06 | 2.67 | -1.89 |
Net Cash from Financing Activities | -7.91 | 111.31 | 20.78 | 16.72 | 73.21 |
Effect of Exchange Rate Changes | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Net Change In Cash & Equivalents | 19.81 | -24.24 | -8.17 | -12.31 | 50.11 |
Cash at Beginning of Period | 12.59 | 36.83 | 45.00 | 57.31 | 7.20 |
Cash at End of Period | 32.40 | 12.59 | 36.83 | 45.00 | 57.31 |
Diluted Net EPS | -0.29 | -0.45 | -1.49 | -1.81 | -2.28 |
Fiscal Year End for Trevi Therapeutics, Inc falls in the month of December.
All data in Millions except Per Share data.
Cash Flow From Operations, Investments & Financial Activities
6/30/2024 | 3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 | |
---|---|---|---|---|---|
Cash Flow From Operations, Investments & Financial Activities |
|||||
Net Income (Loss) | -23.25 | -10.90 | -29.07 | -21.24 | -13.55 |
Depreciation/Amortization & Depletion | 0.07 | 0.04 | 0.30 | 0.27 | -1.07 |
Net Change from Assets/Liabilities | 2.67 | -0.06 | -3.85 | -4.58 | -4.79 |
Net Cash from Discontinued Operations | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Other Operating Activities | 1.37 | 0.46 | 0.90 | 0.21 | 1.33 |
Net Cash From Operating Activities | -19.15 | -10.47 | -31.71 | -25.35 | -18.07 |
Property & Equipment | -0.03 | 0.00 | -0.14 | -0.12 | -0.10 |
Acquisition/ Disposition of Subsidiaries | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Investments | -5.30 | -8.09 | 59.57 | 46.70 | 28.70 |
Other Investing Activities | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Net Cash from Investing Activities | -5.32 | -8.09 | 59.43 | 46.58 | 28.60 |
Uses of Funds
6/30/2024 | 3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 | |
---|---|---|---|---|---|
Issuance (Repurchase) of Capital Stock | 0.25 | 0.00 | 0.14 | 0.11 | 0.10 |
Issuance (Repayment) of Debt | -0.06 | -0.03 | -9.50 | -9.47 | -9.44 |
Increase (Decrease) Short-Term Debt | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Payment of Dividends & Other Distributions | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Other Financing Activities | 4.85 | 0.00 | 1.45 | 1.51 | -0.03 |
Net Cash from Financing Activities | 5.04 | -0.03 | -7.91 | -7.86 | -9.37 |
Effect of Exchange Rate Changes | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Net Change In Cash & Equivalents | -19.43 | -18.59 | 19.81 | 13.38 | 1.16 |
Cash at Beginning of Period | 32.40 | 32.40 | 12.59 | 12.59 | 12.59 |
Cash at End of Period | 12.96 | 13.81 | 32.40 | 25.97 | 13.75 |
Diluted Net EPS | -0.12 | -0.11 | -0.08 | -0.08 | -0.07 |